tetano
Editor, Senior Moderator
Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print] [h=1]Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.[/h]
Keam B[SUP]1,[/SUP][SUP]2[/SUP], Kang CK[SUP]1[/SUP], Jun KI[SUP]1[/SUP], Moon SM[SUP]3[/SUP], Suh KJ[SUP]3[/SUP], Lee DW[SUP]1,[/SUP][SUP]2[/SUP], Ock CY[SUP]1,[/SUP][SUP]2[/SUP], Kim M[SUP]1,[/SUP][SUP]2[/SUP], Choi Y[SUP]4[/SUP], Lim Y[SUP]1,[/SUP][SUP]2[/SUP], Lee KH[SUP]1,[/SUP][SUP]2[/SUP], Kim SH[SUP]3[/SUP], Kim TM[SUP]1,[/SUP][SUP]2[/SUP], Kim TY[SUP]1,[/SUP][SUP]2[/SUP], Oh DY[SUP]1,[/SUP][SUP]2[/SUP], Kim DW[SUP]1,[/SUP][SUP]2[/SUP], Im SA[SUP]1,[/SUP][SUP]2[/SUP], Lee JS[SUP]3[/SUP], Kim ES[SUP]3[/SUP], Kim HB[SUP]3[/SUP], Kim NJ[SUP]1[/SUP], Kim YJ[SUP]3[/SUP], Park WB[SUP]1[/SUP], Oh MD[SUP]1[/SUP].
[h=3]Author information[/h] 1 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. 4 Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
[h=3]Abstract[/h] Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs, n=46) or cytotoxic agents (n=90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results supports administration of annual influenza vaccinations for patients with cancer that receive ICIs.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] Influenza; immune checkpoint inhibitor; immune-related adverse event; immunogenicity; vaccination
PMID: 31680143 DOI: 10.1093/cid/ciz1092
Keam B[SUP]1,[/SUP][SUP]2[/SUP], Kang CK[SUP]1[/SUP], Jun KI[SUP]1[/SUP], Moon SM[SUP]3[/SUP], Suh KJ[SUP]3[/SUP], Lee DW[SUP]1,[/SUP][SUP]2[/SUP], Ock CY[SUP]1,[/SUP][SUP]2[/SUP], Kim M[SUP]1,[/SUP][SUP]2[/SUP], Choi Y[SUP]4[/SUP], Lim Y[SUP]1,[/SUP][SUP]2[/SUP], Lee KH[SUP]1,[/SUP][SUP]2[/SUP], Kim SH[SUP]3[/SUP], Kim TM[SUP]1,[/SUP][SUP]2[/SUP], Kim TY[SUP]1,[/SUP][SUP]2[/SUP], Oh DY[SUP]1,[/SUP][SUP]2[/SUP], Kim DW[SUP]1,[/SUP][SUP]2[/SUP], Im SA[SUP]1,[/SUP][SUP]2[/SUP], Lee JS[SUP]3[/SUP], Kim ES[SUP]3[/SUP], Kim HB[SUP]3[/SUP], Kim NJ[SUP]1[/SUP], Kim YJ[SUP]3[/SUP], Park WB[SUP]1[/SUP], Oh MD[SUP]1[/SUP].
[h=3]Author information[/h] 1 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. 4 Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.
[h=3]Abstract[/h] Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs, n=46) or cytotoxic agents (n=90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results supports administration of annual influenza vaccinations for patients with cancer that receive ICIs.
? The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
[h=4]KEYWORDS:[/h] Influenza; immune checkpoint inhibitor; immune-related adverse event; immunogenicity; vaccination
PMID: 31680143 DOI: 10.1093/cid/ciz1092